Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Thiogenesis Therapeutics Corp TTIPF


Primary Symbol: V.TTI

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the obstacles facing thiol-based drugs, their short half-life, gastrointestinal (GI) side effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for MELAS, Leigh syndrome, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).


TSXV:TTI - Post by User

User Avatar Image
(134)
•••
  • 1StockInformerX
Post by 1StockInformeron Jan 09, 2025 7:44pm
33 Views
Post# 36397024

TTI Advances Lead Drug Targeting Pediatric & Orphan Diseases

TTI Advances Lead Drug Targeting Pediatric & Orphan Diseases

A mid-December financial analysis from Valuation Lab highlights the significant potential of Thiogenesis Therapeutics' (Ticker: TTI.v or TTIPF for US investors) lead compound, TTI-0102, and its ability to address unmet medical needs and multi-billion dollar markets. 

r/wallstreetsmallcaps - Biotech: Thiogenesis Therapeutics (TTI.v) Advances Lead Drug Targeting Pediatric and Orphan Diseases

As highlighted in the report, Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company dedicated to developing thiol-active compounds to treat mitochondrial dysfunctions associated with rare and pediatric diseases which are currently under-addressed.  

The Science Behind TTI-0102

TTI-0102 is a prodrug that improves upon cysteamine, a current treatment for cystinosis, by addressing its known limitations. The compound is under development for: MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes), Leigh Syndrome, Rett Syndrome and Pediatric MASH (Metabolic Associated Steatohepatitis). 

According to Valuation Lab, these diseases collectively represent a potential global peak sales opportunity of CAD 9.8 billion.

Milestones and Strategic Advancements  

The past year saw notable achievements for Thiogenesis Therapeutics which strengthen the company’s intellectual property portfolio and clinical positioning: 

- Securing a European patent for TTI-0102 with protection until 2037  

- Advancing collaborations with leading research institutions  

- Obtaining regulatory approvals for clinical trials  

Key Clinical Catalysts for 2025

The company anticipates significant progress with Phase II proof-of-concept (POC) trials starting next year. The following estimates and projections originate from Valuation Lab’s financial modeling:

MELAS (POC Expected in Q1 2025)  

  - Projected peak sales: CAD 4 billion  

  - Projected success rate upon trial initiation: 15%  

  - rNPV increased by: CAD 10.6 per share  

Leigh Syndrome (POC Expected in H1 2025)  

  - Ultra-rare indication with no approved treatments  

  - Projected peak sales: CAD 40 million  

  - rNPV increase by: CAD 0.1 per share  

Pediatric MASH (POC Expected in H1 2025)  

  - Larger market potential with peak sales estimates of CAD 4 billion  

  - rNPV increased by: CAD 1.6 per share  

r/wallstreetsmallcaps - Biotech: Thiogenesis Therapeutics (TTI.v) Advances Lead Drug Targeting Pediatric and Orphan Diseases

Conclusion  

With its lead drug TTI-0102 advancing toward Phase II trials, Thiogenesis Therapeutics is well-positioned to address high unmet needs in pediatric and orphan diseases. 

Overall, Valuation Lab assigned Thiogenesis a risk-adjusted sum-of-parts valuation of $7.50 per share well above TTI.v's current share price of $0.58.

For more information, access the full report here:  

https://www.valuationlab.com/app/download/8229158562/vL+Thiogenesis+Flash+Update+16DEC24.pdf

Posted on behalf of Thiogenesis Therapeutics Corp.

<< Previous
Bullboard Posts
Next >>